rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2009-5-6-47-50rpcardio-735Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯINTERNATIONAL DIABETES FEDERATION CONSENSUS ON DEFINITION OF THE METABOLIC SYNDROME: FACTS AND COMMENTSКОНСЕНСУС МЕЖДУНАРОДНОЙ ФЕДЕРАЦИИ ДИАБЕТА ПО ОПРЕДЕЛЕНИЮ МЕТАБОЛИЧЕСКОГО СИНДРОМА: ФАКТЫ И КОММЕНТАРИИМамедовМ. Н.MamedovM. N.

101990 Москва, Петроверигский пер., 10

Petroverigsky per. 10, Moscow, 101990

mmamedov@gnicpm.ruГосударственный научно-исследовательский центр профилактической медицины РосмедтехнологийРоссияState Research Center for Preventive Medicine of RosmedtechnologyRussian Federation200911012016564750Copyright © Mamedov M.N., 20162016Мамедов М.Н.Mamedov M.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/735

International Diabetes Federation consensus, devoted to definition of the metabolic syndrome was published in 2006. The main statements of this document are presented and commented.

В 2006 г. был опубликован консенсус Международной Федерации Диабета, посвященный определению метаболического синдрома. Представлены основные положения этого документа и комментарии к нему.

метаболический синдромМеждународная Федерация Диабетаконсенсусmetabolic syndromeInternational Diabetes FederationconsensusReferencesThe IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, 2006. Available at: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdfThe IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, 2006. Available at: http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdfSaad M.F., Lillioja S., Nyomba B.L. et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med. 1991;324(11):733-9.Saad M.F., Lillioja S., Nyomba B.L. et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med. 1991;324(11):733-9.Diabetes and Obesity: Time to Act. International Diabetes Federation (IDF) and International Association for the Study of Obesity (IASO), 2004.Diabetes and Obesity: Time to Act. International Diabetes Federation (IDF) and International Association for the Study of Obesity (IASO), 2004.Brunzell J.D., Ayyobu A.F. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med. 2003;115 Suppl 8A:24S-28S..Brunzell J.D., Ayyobu A.F. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med. 2003;115 Suppl 8A:24S-28S..Robins S.J., Rubins H.B., Faas F.H. et al. Insulin resistance and cardiovascular events with low HDL cho￾lesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26(5):1513-7.Robins S.J., Rubins H.B., Faas F.H. et al. Insulin resistance and cardiovascular events with low HDL cho￾lesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003;26(5):1513-7.Steinmetz A., Fenselau S., Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes 2001:109(4):S548-59.Steinmetz A., Fenselau S., Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes 2001:109(4):S548-59.Lindstrom J., Louheranta A., Mannelin M. et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-6.Lindstrom J., Louheranta A., Mannelin M. et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-6.Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 2005-16.Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 2005-16.Haffner S.M., Alexander C.M., Cook T.J. et al. Reduced coronary events in simvaststin-treated patients with coronary heart disease and diabetes mellitus or impaired fasting glucose level: subgroup analysis on the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159(22):2661-7.Haffner S.M., Alexander C.M., Cook T.J. et al. Reduced coronary events in simvaststin-treated patients with coronary heart disease and diabetes mellitus or impaired fasting glucose level: subgroup analysis on the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159(22):2661-7.Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh repot of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42(6): 1206-52.Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh repot of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42(6): 1206-52.Knowler W.C., Barrett-Connor E., Fowler S.E. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6):393-403.Knowler W.C., Barrett-Connor E., Fowler S.E. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6):393-403.Durbin R.J. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab. 2004;6(4):280-5.Durbin R.J. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab. 2004;6(4):280-5.Chiasson J.L., Josse R.G., Comis R. et al. Stop-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP￾NIDDM trial. JAMA 2003;290(4):486-94.Chiasson J.L., Josse R.G., Comis R. et al. Stop-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP￾NIDDM trial. JAMA 2003;290(4):486-94.Torgerson J.S., Hauptman J., Boldrin M.N., Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomised study of orlistat as an adjunct to lifestyle changes for the preventionof type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.Torgerson J.S., Hauptman J., Boldrin M.N., Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomised study of orlistat as an adjunct to lifestyle changes for the preventionof type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.

The authors declare that there are no conflicts of interest present.